-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
-
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: New share capital registered
-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
-
Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma
